STUDresearch · Peptide
Livagen
Also known as
KEDA · KEDA peptide · Lys-Glu-Asp-Ala · H-Lys-Glu-Asp-Ala-OH · H-KEDA-OH · liver bioregulator · Livagen peptide · Khavinson liver tetrapeptide · SCHEMBL5967826 · lysyl-glutamyl-aspartylalanine
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ / Oral
Longevity & bioregulators
Systemic — liver-directed marketing does not establish liver-selective delivery in humans.
What people say
Livagen is the defined KEDA tetrapeptide marketed as a liver bioregulator. Reviewed formal work is largely cell culture, not a modern human liver-efficacy or distribution program.
Doses people talk about
An ambiguous 0.5 mg–1 g reply in one thread concerned Ovagen and appears to contain a typo; it is not attributed to Livagen or converted into a dose.
How it may feel
Public experience is sparse and conflicted: one user reported serious anxiety and heart symptoms during a 12-day course, one positive source was promotional, and a heavily confounded multi-agent account claimed fast liver-enzyme changes.
Short-course chart~5–10 mg KEDA once daily
Injectable research-chart amount for about 10 days; no modern human efficacy or PK validation was found.
Mid-band chart~2–5 mg KEDA SubQ once daily
Community chart for roughly 10–20 days; some charts extend the 2 mg amount toward 30 days.
Oral product-chart range~10–40 mg labeled material/day oral
Derived from 10 mg product labels and one-to-two capsules once or twice daily; mixed peptide complexes and pure KEDA are not established as bioequivalent.
Half-life & effect duration
- Half-life in the body
- Oral or injectedNo settled estimate
- Felt duration people report
- Adverse accountSevere symptoms linked to a 12-day course reportedly persisted for months
- Multi-agent accountLab changes within days
Cycles people discuss
Published human cycle evidence was not found. Vendor and community charts range from roughly 10-day blocks to longer schedules, with no validated universal cadence.
Timing
During on-blocks, once-daily use at morning or another consistent clock time dominates; split twice-daily timing is mainly an oral product-insert pattern. These are practice conventions, not a validated optimum.
Stacks
Livagen is often discussed beside Ovagen or larger bioregulator and supplement stacks. The clearest public outcome report also used other agents, so Livagen-specific attribution is not possible.
Watch for
No published modern toxicology package: Skeptical reference summaries note absence of robust clinical tolerability databases for pure KEDA.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No measured human systemic half-life for oral or injected KEDA was identified.
The reviewed PubMed papers exposed cultured hepatocytes or lymphocytes; daily community charts and small-peptide expectations are not human PK measurements.
Search was bounded to product identity, indexed KEDA literature and actual community reports; absence here is not proof that no inaccessible study exists.
- Khavinson et al. — Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages: Norm and effect of the peptide Livagen (opens in a new tab)Abstract describes synthetic Lys-Glu-Asp-Ala exposure in cultured hepatocytes from young and old rats and changes in protein synthesis, greatest in old cells.Ex vivo rat-cell study; no intact-animal or human absorption, distribution, half-life, efficacy or safety measurement.
- Khavinson et al. — Effects of Livagen peptide on chromatin activation in lymphocytes from old people (opens in a new tab)Abstract reports chromatin effects after Livagen exposure in cultured lymphocytes from older people.Ex vivo cell-culture endpoint; not oral or injected human exposure, pharmacokinetics or clinical liver benefit.
- Lezhava et al. — Anti-aging peptide bioregulators induce reactivation of chromatin (opens in a new tab)Abstract describes cultured lymphocytes from older subjects and chromatin changes with peptide bioregulator exposure.Ex vivo laboratory work from the originator research line; does not establish human systemic delivery, PK, liver targeting or clinical outcome.
Felt duration people report
One user linked severe symptoms to a 12-day course and said they persisted for months; another multi-agent report claimed laboratory change within days.
The positive report used Ovagen, Livagen and other interventions, while the adverse post omitted amount and route.
Sparse, uncontrolled and unverified accounts; promotional participation and multi-agent use sharply limit causal interpretation.
- r/Peptides — Experiences with Livagen (opens in a new tab)Visible replies include one promotional positive source with a vendor plug and a separate user reporting severe anxiety and heart symptoms after 12 days, claimed to persist eight months; no amount or route is given for the adverse account.Sparse thread, unverified products and outcomes; promotional contamination in one reply and no clinical adjudication of the serious adverse report.
- r/Peptides — Best peptides for the liver? (opens in a new tab)One author says injectable bioregulators felt more noticeable than pills and claims liver enzymes normalized within days after adding injectable Ovagen and Livagen; the thread also mentions stem cells, TUDCA and other agents. A later ambiguous dose reply appears to refer to Ovagen, not Livagen.Heavy co-use, no visible laboratory documents, unclear chronology and an ambiguous likely-typo dose reply; no Livagen-specific amount or causal attribution.
What people say
- Subjective ‘liver load’: Community anecdotes after alcohol phases, training bulk, or polypharmacy — heavily confounded by diet, alcohol cut, and multi-agent stacks. forum
- Stack halo: Often credited inside multi-bioregulator posts (Livagen + Ovagen + Vesugen, etc.); single-agent credit unreliable. forum
- Aged hepatocytes (culture): Nanomolar KEDA increased biosynthetic activity in old-rat hepatocyte monolayers, approaching young-cell protein-synthesis rates. animal
- Circadian protein rhythm: Same culture line cited for restoring age-damped circumhoralian/circadian rhythms of protein synthesis in aged hepatocyte cultures. animal
- Lymphocyte chromatin (elderly donors): 2002 Bull Exp Biol Med work — Livagen induced ribosomal-gene activation, decondensation of pericentromeric structural heterochromatin, and release of genes repressed by age-related euchromatin condensation (de-heterochromatinization). lab
- Multi-peptide chromatin panel: 2004 short-peptide comparison in leukocytes from subjects ~75–88 years — Livagen among peptides (with Epithalon, Prostamax, etc.) that activated ribosome genes and decondensed packed chromatin; Livagen and Epithalon also altered chromosome-9 pericentromeric patterns. lab
- Enkephalinase inhibition: Livagen IC50 ~20 µM vs Epitalon ~500 µM on human-serum enkephalin-degrading enzymes; stronger than some classic peptidase inhibitors in that assay — mechanism talk for endogenous opioid tone / pain modulation without direct receptor agonism. lab
- Digestive enzymes (rats, oral): Multi-week oral Livagen — peptide described as weakly hydrolyzed by small-intestine hydrolases; age-dependent shifts in digestive enzyme activity (activity fell toward normal in young, rose toward young controls in old). animal
- Hepatoprotection models: Developer-adjacent reviews and model writeups cite antioxidant normalization, ALT/AST/bilirubin/cholesterol shifts, and stromal/glycogen markers in experimental hepatitis/fibrosis-style stress — animal/model signals, not licensed therapy. animal
- Immune markers (lab models): Vendor/review summaries cite shifts in CD3+/CD4+/CD8+ vs CD22+ lymphocyte markers and neutrophil phagocytosis in suspensions / viral hepatitis A contexts — not large independent RCTs. lab
- Tissue-explant / aging narrative: Some secondary summaries cite increased aged-rat liver explant growth metrics and multi-tissue chromatin stories — still preclinical depth. animal
- What it is not proven for: No high-quality Western evidence that it treats hepatitis, cirrhosis, MASH/NAFLD, alcohol-related liver disease, or extends human lifespan. trial
Doses people talk about
- Classic short high-band (injectable research charts): ~5–10 mg once daily × ~10 consecutive days (~50–100 mg total KEDA per course) — mirrors other high-band Khavinson short-course templates. forum
- Intensive 10 mg note: Higher ~10 mg daily often paired with shorter ~10–14 day blocks rather than long continuous runs in writeups that distinguish ‘intensive’ from mid-band. forum
- Common mid injectable band: ~2–5 mg subcutaneous once daily × ~10–20 days; some guides extend toward ~30 days at ~2 mg. forum
- Lower research-vial titration band: ~500 mcg–2 mg (0.5–2.0 mg) once daily, stepped up over multi-week charts (often 8–12 weeks) on 20 mg vial educational pages. forum
- Example 20 mg vial titration table (educational vendor style): Weeks 1–2: ~500 mcg daily; weeks 3–4: ~1,000 mcg; weeks 5–6: ~1,500 mcg; weeks 7–12: ~2,000 mcg — not a validated clinical protocol. forum
- Route frequency in-course: Once daily during on-blocks dominates (AM or consistent clock time); split BID oral is product-insert style more than injection culture. forum
- Sublingual improvisation: Occasional discussion of sublingual/buccal to bypass gut — tetrapeptide sublingual BA not rigorously established; subq remains the reliability default in research-chem talk. forum
- Pulse vs continuous: Short courses a few times/year preferred over year-round daily open-ended use in Khavinson-style practice talk. forum
- Course totals people track (injectable charts): Roughly ~20–40 mg (2 mg × 10–20), ~50–100 mg (5–10 mg × 10), ~60 mg (2 mg × 30), or multi-vial totals on long 0.5–2 mg titration courses — chart family dependent. forum
- Uncertainty / gray market: Label purity, under-dose, mislabel (other ‘-gen’ swaps), and KEDA vs multi-peptide liver complexes — COA/HPLC claims vary; label ≠ delivered KEDA. forum
- Oral capsule / cytogen-style kits: Marketed bioregulator lines often use ~10 mg capsules; common insert-style patterns are 1–2 capsules once or twice daily for ~10–20 days (roughly ~10–40 mg labeled material/day depending on chart), sometimes framed as ~20 mg/day (2×10 mg) for ‘intensive’ oral liver talk. forum
- Oral vs injectable mg equivalence: Poorly standardized — capsule ‘10 mg complex’ labels, Cytogen/Cytomax-style products, and pure lyophilized KEDA mg are not proven bioequivalent; do not copy oral kit mg onto research vials without identity check. forum
- Widely repeated 2 mg / 30-day chart: ~2 mg subq daily × ~30 days, repeated ~2–3×/year — pulsatile bioregulator framing (signal, not continuous drug). forum
- Framing: Discussed community, vendor-chart, and Khavinson-style practice ranges only — not medical advice, not prescriptions, not FDA-labeled dosing. No standardized modern human clinical dose is established. forum
How it may feel
- During the first 12 days: One user reported severe anxiety and heart symptoms that they said persisted for months; the amount and route were not stated, and causality cannot be established from the post. forumanecdote
- Days to weeks: One heavily confounded injectable account claimed liver enzymes normalized within days after adding Ovagen and Livagen; the same user also described oral bioregulator effects as subtler than injections. forum
- End of 10–20 day short course: Common checkpoint — mild recovery/energy, ‘liver feel’ stories, or explicit null. forum
- End of ~30-day mid-dose courses (2 mg-style charts): Same subtle-or-null pattern; responders frame it as regulatory, not a daily drug buzz. forum
- Weeks 2–8 post-course: Residual interest framed as downstream gene-expression / ‘reset’ window rather than residual plasma drug. anecdote
- Months 3–6: Talk shifts to 2–3 short courses/year (or seasonal re-runs after hepatic-load phases), not continuous daily. forum
- Titration 8–12 week low-mcg charts: Gradual 0.5→2 mg daily schedules exist on vendor pages; subjective checkpoints are weekly, not day-1 drama. forum
- No change after one course: Forums re-check alcohol, meds, product identity (KEDA vs other ‘-gen’), purity, route, oral vs injectable expectations, and dose-unit math (mcg vs mg) — not auto mega-dose. forum
Cycles people discuss
- Short high-band block: ~10 consecutive days at ~5–10 mg/day — dominant ‘classic bioregulator course’ pattern in many charts. forum
- Standard short block: ~10–20 consecutive days at mid-band daily mg. forum
- Extended mid block: ~20–30 days (especially ~2 mg daily charts). forum
- Long titration minority: ~8–12 weeks (sometimes discussed to ~16) at 0.5–2 mg daily with gradual steps — research-vial educational schedules, not originator clinic standard. forum
- Off-period (short-course culture): Multi-week to multi-month rests; commonly ~6–12 weeks minimum between short cycles, or ~2–3 runs/year with seasonal spacing. forum
- Oral kit cadence: 10–20 day capsule courses, 2–3×/year, multi-month gaps — parallel to other cytogen bioregulators. forum
- Re-runs: Calendar-based (spring/fall) or after high hepatic-load phases (alcohol, meds, bulk); multi-year controlled safety databases for gray-market KEDA are not established. forum
- Not continuous daily forever: Bioregulator culture favors short on-blocks with long gaps so claimed epigenetic/gene-expression changes can settle. forum
- No single validated cadence: Practice-pattern talk only — no proven human cycle standard from modern RCTs. forum
- Judge horizon: Subjective digestion/energy within or just after a course; any ‘longevity’ framing judged across months of pulsed use if at all. forum
Timing
- No measured human systemic half-life: Daily course charts and hours-scale assumptions are community convention; the reviewed KEDA cell-culture papers do not supply human injection or oral PK. trialforum
- Why short courses anyway: Bioregulator practice history + chromatin/gene-expression ‘programming’ narrative drive 10–30 day bursts more than long plasma t½ math. forum
- Downstream vs ‘still in blood’: Users separate acute peptide presence from days–weeks of claimed residual reset after the last dose. anecdote
- PK gap: Formal human absorption, distribution, half-life, bioavailability, and clearance packages for gray-market Livagen are essentially absent — dosing culture is not PK-driven. trial
- Structural expectation: Small linear unprotected tetrapeptide → rapid peptidase breakdown and short systemic presence expected, similar to related Khavinson tetrapeptides. trial
- Oral stability signal: Rat digestive work described Livagen as weakly hydrolyzed by small-intestine peptide hydrolases — used in oral-route advocacy, not proof of full human oral bioequivalence to injection. animal
- Nanomolar tissue logic: In-vitro chromatin/hepatocyte signals at nM concentrations are cited to argue mid-mg systemic charts may be ‘signal’ doses — still not a human BA package. lab
More on what it is
- Why people search it: Liver-support + bioregulator longevity catalogs; chromatin/immune-aging narratives; dual-liver stacks with Ovagen; far less forum volume than BPC-157, TB-500, or Epitalon. forum
- What it is: Synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA); molecular formula ~C18H31N5O9; molecular weight ~461.5 g/mol; CAS often listed ~433257-50-2. Defined short Khavinson-class bioregulator historically associated with liver tissue analysis, not a crude organ extract. trial
- Claimed mechanism (chromatin): De-heterochromatinization — unpacking age-condensed chromatin, activating ribosomal genes, releasing genes silenced by age-related euchromatin condensation in elderly-donor lymphocytes. lab
- Claimed mechanism (liver): Nanomolar KEDA restored protein synthesis and circadian biosynthetic rhythm in old-rat hepatocyte cultures toward young levels — framed as gene-regulatory, not a stoichiometric ‘drug flood.’ animal
- Claimed mechanism (enzymes): 2003 human-serum assay — Livagen inhibited enkephalin-degrading enzymes more potently than Epitalon (IC50 ~20 µM vs ~500 µM); did not appear to bind opioid receptors directly. lab
- Evidence posture: Older Russian/Georgian Khavinson–Lezhava-line work (chromatin, hepatocytes, digestive enzymes, enkephalinase) is denser than modern Western human RCTs; independent replication outside the originator network is sparse; no completed modern Western efficacy trials for clinical liver disease. trial
- Sequence family note: Same first three residues as Prostamax (KEDP) and Pancragen (KEDW) with a different fourth amino acid — tissue assignment (liver vs prostate vs pancreas) is Khavinson theory, not head-to-head comparative trial proof. trial
- Not the same as: Not a steroid, GH secretagogue, milk thistle, TUDCA, NAC, crude liver extract (e.g. Svetinorm/Ventvil-class polypeptide complexes), Survodutide/LIVERAGE (unrelated MASH drug), or milligram-for-milligram Ovagen (different sequence / framing). trial
Stacks
- Vascular + liver trio: Livagen + Ovagen + Vesugen (endothelial/vascular bioregulator) for ‘hepatic + vascular map’ longevity stacks. forum
- Digestive multi-organ kit talk: Livagen alongside Svetinorm (crude liver peptide complex — not identical to KEDA), Stamakort (stomach), Suprefort/Pancragen (pancreas), Ventfort (vascular) in broader GI–metabolic bioregulator kits. forum
- Pineal / longevity core: Livagen + Epitalon (AEDG) — different tissues (liver/chromatin vs pineal/telomere stories); often same short-course calendar. forum
- Immune pairing: Livagen + Thymalin or Vilon; some longevity pages also mention Thymosin Alpha-1 / LL-37 as non-bioregulator immune adjuncts — confounded multi-agent logs. forum
- OTC liver adjacency: NAC, milk thistle (silymarin), TUDCA, alpha-lipoic acid commonly co-listed — credit for labs/feel often shared across the stack. forum
- Healing peptides (adjacent, not classic Khavinson): Occasional co-use with BPC-157 or gut-repair talk during ‘liver load’ windows — different mechanism class. forum
- Lifestyle co-credit: Alcohol reduction, sleep, training deload, and diet changes frequently get equal or greater credit when outcomes feel good. forum
- Stack ratio honesty: Unlike Wolverine/GLOW pre-mixes, bioregulator stacks are almost always separate products with independent dose charts; no universal Livagen:Ovagen mg ratio is validated. forum
- Liver dual (most common bioregulator pair): Livagen + Ovagen — framed as complementary liver coverage (KEDA chromatin / protein-synthesis narrative + Ovagen liver–GI function framing; different sequences). Ratios are separate daily doses of each, not a fixed pre-mix. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, sting, itch, or bruise — worse with poor technique, large volumes, or same-site repeats. forum
- Nonspecific systemic: Mild headache, fatigue, or GI unease appear in minority stack logs — hard to attribute to KEDA alone. forum
- Null feel: Many report no subjective change after a full short course; null is common, not proof of ‘broken product’ alone. forum
- Source quality / contamination: Under-dose, mislabel, wrong sequence, or contaminants are structural gray-market risks; impure injectables can theoretically harm the organ people hope to support. forum
- Not liver-disease therapy: Preclinical and developer-adjacent model signals ≠ treatment for hepatitis, fibrosis, cirrhosis, MASH, or acute liver failure — do not replace workup or approved care. forum
- Drug / alcohol interactions: No solid interaction charts with common meds or alcohol; stacking with hepatotoxic agents is uncharted. forum
- WADA / athletes: Not individually named on common prohibited-list summaries, but unapproved substances can fall under catch-all S0-style rules depending on jurisdiction — athletes should verify with their ADO. forum
- Research-only label: Sold as research chemical / not for human consumption in many markets; self-use outside approved pathways varies by jurisdiction. forum
- Safety DB gap: Anecdotal ‘well tolerated like other bioregulators’ ≠ controlled modern human risk data or long-term surveillance. forum
- No published modern toxicology package: Skeptical reference summaries note absence of robust clinical tolerability databases for pure KEDA. trial
- Identity confusion: Survodutide (LIVERAGE) MASH trials are unrelated; Svetinorm/Ventvil-class liver extracts are not pure KEDA; Prostamax/Pancragen share KED- prefixes but different fourth residues. trial
- Special populations: Pregnancy, nursing, children, active malignancy, decompensated liver disease, and complex polypharmacy — unknowns; research-only framing. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.